Henry Schein Q2 Sales Rise 6.7%, EPS Beats, Full-Year Guidance Raised
HSIC sits 42% above its 52-week low of $61.945.
Summary
Henry Schein reported Q2 2026 net sales of $3.5 billion, up 6.7%, with non-GAAP EPS of $1.27 beating estimates. The company raised its full-year guidance for sales and EPS.
Key Events · Earnings and Guidance · HSIC
-
Q2 Sales Rise 6.7%
Net sales reached $3.458 billion, driven by 4.6% internal growth and 1.4% foreign exchange benefit. Global Dental merchandise led with a 9.7% increase.
-
EPS Beats Estimates
Non-GAAP diluted EPS of $1.27 exceeded consensus, up from $1.18 a year ago. GAAP diluted EPS was $0.82.
-
Full-Year Guidance Raised
Management increased its 2026 outlook for both net sales and non-GAAP EPS, citing strong demand and operational execution.
-
Restructuring Charges Continue
The company recorded $29 million in restructuring costs in Q2 and $41 million year-to-date under its 2024 Plan, aimed at integrating acquisitions and improving efficiency.
Analysis · HSIC · Trade & Services
Henry Schein delivered a strong second quarter, with net sales climbing 6.7% to $3.5 billion and non-GAAP EPS of $1.27 topping estimates. Management raised its full-year outlook for both sales and earnings, signaling confidence in sustained demand across dental and medical distribution. The results come against a backdrop of ongoing restructuring — $41 million in charges year-to-date — and a leadership transition to new CEO Frederick Lowery. The combination of an earnings beat, raised guidance, and a new chief executive makes this a pivotal update for investors.
At the time of this filing, HSIC was trading at $87.73 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $10B. The 52-week trading range was $61.95 to $92.18. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.